Cosponsor
Sign in

S 1040 · introduced · significant

Drug Competition Enhancement Act

What this bill does

  • The bill prohibits drug manufacturers from switching to modified versions of drugs to avoid generic competition when patents expire.
  • Drug manufacturers and consumers who pay for medications are affected by this competition enforcement rule.
  • The FTC can investigate violations and seek court orders to stop the practice and recover profits gained unfairly.

Generated by claude-haiku-4-5

Community Threads

Started by Cosponsor

  1. 01

    How might preventing drug makers from switching to modified versions affect the timeline for generic drugs reaching patients?

  2. 02

    What evidence supports the claim that patent switching currently delays generic competition and increases medication costs?

  3. 03

    How would the FTC's enforcement authority and resources need to change to investigate and prosecute these violations effectively?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.

Sponsor · R-TX

John Cornyn

Citizen cosponsors

0

In Congress

3/ 100

Senators cosponsoring

Introduced 2025-04-10

Joining the bill

Legislative timeline

  1. 2025-04-10 · senate · Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.

  2. 2025-04-10 · senate · Committee

    Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.

  3. 2025-04-10 · Committee

    Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.

  4. 2025-04-03 · senate · Committee

    Committee on the Judiciary. Ordered to be reported with an amendment favorably.

  5. 2025-03-13 · senate · IntroReferral

    Read twice and referred to the Committee on the Judiciary.

  6. 2025-03-13 · IntroReferral

    Introduced in Senate

Congress.gov ↗

Citizen comments

Sign in to comment on this bill.

No comments yet — be the first.